Free Trial
→ Musk’s Project Colossus could mint millionaires (From Brownstone Research) (Ad) Buy CLOV Stock  Free CLOV Stock Alerts

Clover Health Investments (CLOV) Financials

Clover Health Investments logo
$3.18 +0.05 (+1.60%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$3.14 -0.05 (-1.42%)
As of 05/30/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Clover Health Investments

Annual Income Statements for Clover Health Investments

This table shows Clover Health Investments' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Income / (Loss) Attributable to Common Shareholders		 -43 -213 -340 -588 -136 -364
Consolidated Net Income / (Loss)		 -43 -213 -340 -588 -136 -364
Net Income / (Loss) Continuing Operations		 -46 -210 -255 -588 -136 -364
Total Pre-Tax Income 		-46 -210 -254 -654 -56 -364
Total Revenue		 1,371 1,256 1,106 1,469 731 285
Net Interest Income / (Expense)		 0.00 0.00 0.00 -3.19 -36 -23
Total Interest Income		 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Expense		 0.00 0.00 0.00 3.19 36 23
Total Non-Interest Income		 1,371 1,256 1,106 1,472 767 308
Other Service Charges		 26 25 12 4.94 7.19 5.34
Net Realized & Unrealized Capital Gains on Investments		 -0.47 -4.73 9.22 0.00 94 -139
Premiums Earned		 1,345 1,236 1,085 799 666 457
Total Non-Interest Expense		 1,417 1,466 1,360 2,123 787 648
Salaries and Employee Benefits		 232 257 279 260 71 92
Property & Liability Insurance Claims		 1,006 997 900 1,662 573 454
Other Operating Expenses		 176 183 204 185 121 99
Depreciation Expense		 1.33 2.51 1.19 1.25 0.56 0.55
Amortization Expense		 0.00 0.00 0.03 14 21 -
Impairment Charge		 0.00 16 0.00 0.00 - -
Restructuring Charge		 0.29 9.82 0.00 0.00 - -
Other Special Charges		 0.00 0.00 -23 - 0.00 2.91
Other Gains / (Losses), net		 -0.05 -0.09 0.90 66 -80 -
Net Income / (Loss) Discontinued Operations		 3.26 -3.21 -85 - - -
Weighted Average Basic Shares Outstanding		 490.02M 482.18M 476.24M 412.92M 88.69M 87.83M
Weighted Average Diluted Shares Outstanding		 490.02M 482.18M 476.24M 412.92M 88.69M 87.83M
Weighted Average Basic & Diluted Shares Outstanding		 510.91M 495.29M 479.55M 473.27M 21.18M -

Quarterly Income Statements for Clover Health Investments

This table shows Clover Health Investments' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -1.27 -22 -9.16 7.41 -19 -70 -41 -29 -73 -84 -75
Consolidated Net Income / (Loss)		 -1.27 -22 -9.16 7.41 -19 -70 -41 -29 -73 -84 -75
Net Income / (Loss) Continuing Operations		 -1.27 -21 -8.79 7.17 -23 -68 -34 -29 -80 0.74 -75
Total Pre-Tax Income 		-1.27 -21 -8.79 7.19 -23 -68 -34 -29 -80 1.17 -75
Total Revenue		 462 337 331 356 346 308 306 320 322 -1,481 855
Net Interest Income / (Expense)		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 1.20 -0.40
Total Interest Income		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Interest Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -1.20 0.40
Total Non-Interest Income		 462 337 331 356 346 308 306 320 322 -1,482 856
Other Service Charges		 5.43 6.28 8.41 6.36 5.20 9.32 4.80 5.76 4.91 5.93 3.61
Premiums Earned		 457 331 323 350 342 303 301 314 317 270 268
Total Non-Interest Expense		 464 358 340 349 370 376 340 349 402 -1,482 931
Salaries and Employee Benefits		 59 63 55 55 59 65 61 62 69 69 70
Property & Liability Insurance Claims		 353 243 250 248 265 247 236 239 275 -1,606 812
Other Operating Expenses		 51 52 35 44 45 45 41 42 56 79 48
Depreciation Expense		 0.47 0.34 0.34 0.33 0.32 0.67 0.56 1.00 0.28 -0.84 0.62
Restructuring Charge		 0.00 - -0.54 0.47 0.35 1.95 1.31 4.75 1.81 - 0.00
Other Gains / (Losses), net		 0.00 - 0.00 -0.02 - - 0.00 0.00 - - -
Net Income / (Loss) Discontinued Operations		 0.00 -0.61 -0.37 0.24 4.00 -2.53 -7.85 0.08 7.09 - -
Weighted Average Basic Shares Outstanding		 497.06M 490.02M 490.18M 487.48M 486.37M 482.18M 480.77M 479.16M 478.81M 476.24M 477.69M
Weighted Average Diluted Shares Outstanding		 497.06M 490.02M 490.18M 495.18M 486.37M 482.18M 480.77M 479.16M 478.81M 476.24M 477.69M
Weighted Average Basic & Diluted Shares Outstanding		 508.92M 510.91M 501.11M 497.47M 1.05B 495.29M 487.64M 484.86M 1.05B 479.55M 477.94M

Annual Cash Flow Statements for Clover Health Investments

This table details how cash moves in and out of Clover Health Investments' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Change in Cash & Equivalents		 18 -9.72 -114 208 25 -7.81
Net Cash From Operating Activities		 35 -145 -204 -282 -118 -160
Net Cash From Continuing Operating Activities		 82 -35 -305 -282 -118 -160
Net Income / (Loss) Continuing Operations		 -43 -213 -340 -588 -136 -364
Consolidated Net Income / (Loss)		 -43 -213 -340 -588 -136 -364
Depreciation Expense		 -1.19 -1.51 -0.32 1.45 0.36 -2.31
Amortization Expense		 0.05 0.09 -0.87 -52 101 16
Non-Cash Adjustments to Reconcile Net Income		 114 154 39 311 17 16
Changes in Operating Assets and Liabilities, net		 12 25 -2.36 45 -101 174
Net Cash From Discontinued Operating Activities		 -48 -110 101 - - -
Net Cash From Investing Activities		 0.57 140 95 -435 137 -182
Net Cash From Continuing Investing Activities		 0.57 140 95 -435 137 -182
Purchase of Property, Leasehold Improvements and Equipment		 -1.56 -0.58 -4.47 -0.72 -0.69 -0.02
Purchase of Investment Securities		 -201 -176 -386 -876 -174 -507
Sale and/or Maturity of Investments		 203 316 485 442 312 325
Net Cash From Financing Activities		 -17 -5.07 -4.96 925 5.84 334
Net Cash From Continuing Financing Activities		 -17 -5.07 -4.96 925 5.84 334
Issuance of Common Equity		 0.90 1.15 1.40 290 1.75 0.60
Repurchase of Common Equity		 -18 -6.22 -6.36 -0.23 -0.96 0.00

Quarterly Cash Flow Statements for Clover Health Investments

This table details how cash moves in and out of Clover Health Investments' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -39 -93 33 47 32 -175 -41 120 87 -197 58
Net Cash From Operating Activities		 -16 -86 50 45 26 -258 -19 53 79 -209 102
Net Cash From Continuing Operating Activities		 -16 -47 50 54 26 -115 -32 33 79 -310 102
Net Income / (Loss) Continuing Operations		 -1.27 -22 -9.16 7.41 -19 -70 -41 -29 -73 -84 -75
Consolidated Net Income / (Loss)		 -1.27 -22 -9.16 7.41 -19 -70 -41 -29 -73 -84 -75
Depreciation Expense		 0.03 -0.04 -0.18 -0.62 -0.35 -0.24 -0.69 2.40 -2.98 -1.61 -0.08
Non-Cash Adjustments to Reconcile Net Income		 26 29 28 36 21 53 33 11 56 -27 36
Changes in Operating Assets and Liabilities, net		 -41 -54 31 11 24 -97 -24 48 98 -196 141
Net Cash From Discontinued Operating Activities		 0.00 -39 0.14 - - -144 14 - - - -
Net Cash From Investing Activities		 8.93 -1.44 -12 4.95 9.19 84 -20 66 10 13 -43
Net Cash From Continuing Investing Activities		 8.93 -1.44 -12 4.95 9.19 84 -20 66 10 13 -43
Purchase of Property, Leasehold Improvements and Equipment		 -0.19 -0.32 -0.40 -0.40 -0.45 0.26 -0.24 -0.35 -0.25 -3.88 -0.26
Purchase of Investment Securities		 -33 -48 -102 -28 -24 -33 -68 -6.26 -68 -109 -107
Sale and/or Maturity of Investments		 42 47 90 33 34 117 48 73 78 125 64
Net Cash From Financing Activities		 -32 -6.14 -4.67 -3.20 -3.36 -0.83 -1.96 -0.15 -2.13 0.06 0.13
Net Cash From Continuing Financing Activities		 -32 -6.14 -4.67 -3.20 -3.36 -0.83 -1.96 -0.15 -2.13 0.06 0.13
Issuance of Common Equity		 0.22 0.66 0.22 0.02 0.00 0.00 0.03 0.27 0.85 0.10 0.41
Repurchase of Common Equity		 -32 -6.80 -4.89 -3.22 -3.36 -0.83 -1.99 -0.42 -2.98 -0.04 -0.28

Annual Balance Sheets for Clover Health Investments

This table presents Clover Health Investments' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Total Assets		 581 571 809 951 267 0.10
Cash and Due from Banks		 195 116 104 300 92 0.00
Trading Account Securities		 243 229 328 197 55 0.00
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00
Customer and Other Receivables		 52 64 71 48 39 -
Premises and Equipment, Net		 5.31 5.08 5.75 2.29 2.08 -
Unearned Premiums Asset		 41 22 20 35 35 -
Intangible Assets		 2.99 2.99 20 4.23 4.23 -
Other Assets		 42 131 160 353 40 0.00
Total Liabilities & Shareholders' Equity		 581 571 809 951 267 0.10
Total Liabilities		 240 284 452 411 433 0.12
Other Short-Term Payables		 214 261 200 184 139 0.12
Other Long-Term Liabilities		 26 23 20 19 162 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 341 286 357 539 -613 -0.02
Total Preferred & Common Equity		 341 286 357 535 -617 -0.02
Total Common Equity		 341 286 357 535 -617 -0.02
Common Stock		 2,577 2,461 2,319 2,154 412 0.00
Retained Earnings		 -2,203 -2,160 -1,946 -1,617 -1,029 -0.02
Treasury Stock		 -31 -13 -6.51 -0.15 0.00 -
Accumulated Other Comprehensive Income / (Loss)		 -1.58 -2.37 -9.37 -1.93 0.01 -

Quarterly Balance Sheets for Clover Health Investments

This table presents Clover Health Investments' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 584 653 674 672 1,060 1,258 1,454 1,558
Cash and Due from Banks		 155 288 255 208 299 310 191 383
Trading Account Securities		 235 242 218 223 305 273 292 247
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Customer and Other Receivables		 54 37 67 84 52 51 57 59
Premises and Equipment, Net		 5.03 5.34 5.28 5.21 4.57 4.62 4.55 2.53
Unearned Premiums Asset		 85 21 54 71 16 2.06 70 14
Intangible Assets		 2.99 2.99 2.99 2.99 19 19 20 4.23
Other Assets		 47 56 72 77 314 516 739 836
Total Liabilities & Shareholders' Equity		 584 653 674 672 1,060 1,258 1,454 1,558
Total Liabilities		 248 311 349 379 738 927 1,130 1,166
Other Short-Term Payables		 216 276 323 355 279 293 329 296
Other Long-Term Liabilities		 32 33 25 23 19 20 20 17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 336 342 325 292 322 331 323 392
Total Preferred & Common Equity		 336 342 325 292 322 331 323 392
Total Common Equity		 336 342 325 292 322 331 323 392
Common Stock		 2,603 2,546 2,518 2,490 2,428 2,395 2,359 2,281
Retained Earnings		 -2,204 -2,181 -2,172 -2,179 -2,089 -2,048 -2,019 -1,872
Treasury Stock		 -63 -24 -19 -16 -12 -9.91 -9.49 -6.47
Accumulated Other Comprehensive Income / (Loss)		 -0.07 0.85 -2.26 -2.56 -5.07 -6.72 -7.03 -11

Annual Metrics And Ratios for Clover Health Investments

This table displays calculated financial ratios and metrics derived from Clover Health Investments' official financial filings.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Growth Metrics		 - - - - - -
Revenue Growth		 9.15% 13.57% -24.72% 101.03% 156.65% 0.00%
EBITDA Growth		 77.61% 17.18% 63.78% -1,641.00% 113.07% 0.00%
EBIT Growth		 78.00% 17.35% 61.13% -1,066.35% 84.58% 0.00%
NOPAT Growth		 78.00% 17.35% 61.13% -1,066.35% 84.58% 0.00%
Net Income Growth		 79.84% 37.17% 42.23% -330.93% 62.50% 0.00%
EPS Growth		 0.00% 0.00% 0.00% 7.79% 62.80% 0.00%
Operating Cash Flow Growth		 124.09% 29.06% 27.77% -138.25% 25.88% 0.00%
Free Cash Flow Firm Growth		 -159.87% 218.37% 89.12% -109,338.83% 0.00% 0.00%
Invested Capital Growth		 19.12% -50.53% -8.68% 1,758.17% -216,733.99% 0.00%
Revenue Q/Q Growth		 2.18% 335.63% -63.37% 22.48% 0.00% 0.00%
EBITDA Q/Q Growth		 49.58% -46.05% 49.58% -65.68% 0.00% 0.00%
EBIT Q/Q Growth		 50.11% -48.95% 42.57% -24.21% 0.00% 0.00%
NOPAT Q/Q Growth		 50.11% -48.95% 42.57% -24.21% 0.00% 0.00%
Net Income Q/Q Growth		 52.94% 6.06% 23.27% -11.54% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 36.61% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 125.36% -50.78% -172.87% -7.74% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 -124.77% -59.30% 88.75% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 -0.30% -62.25% -52.35% 46.67% 0.00% 0.00%
Profitability Metrics		 - - - - - -
EBITDA Margin		 -3.46% -16.84% -23.09% -47.99% 6.26% -122.97%
EBIT Margin		 -3.37% -16.73% -22.98% -44.52% -7.67% -127.75%
Profit (Net Income) Margin		 -3.14% -16.99% -30.71% -40.02% -18.67% -127.77%
Tax Burden Percent		 93.06% 101.57% 133.61% 89.88% 243.28% 100.01%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -10.31% -33.98% -29.34% -153.68% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -93.73% -131.45% -270.92% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -32.35% -46.44% -160.74% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -66.34% -75.78% -314.42% 164.86% 2,063,053.71%
Cash Return on Invested Capital (CROIC)		 -27.76% 33.63% -20.27% -178.24% 0.00% 0.00%
Operating Return on Assets (OROA)		 -8.03% -30.46% -28.89% -107.37% -41.94% -362,436.97%
Return on Assets (ROA)		 -7.47% -30.94% -38.60% -96.51% -102.03% -362,482.81%
Return on Common Equity (ROCE)		 0.00% -66.34% -75.45% 68.69% 614.86% 2,063,053.71%
Return on Equity Simple (ROE_SIMPLE)		 -12.61% -74.50% -95.15% -109.78% 22.10% 0.00%
Net Operating Profit after Tax (NOPAT)		 -32 -147 -178 -458 -39 -255
NOPAT Margin		 -2.36% -11.71% -16.09% -31.16% -5.37% -89.43%
Net Nonoperating Expense Percent (NNEP)		 0.00% 59.74% 102.11% 117.24% 152.73% 0.00%
SG&A Expenses to Revenue		 16.96% 20.48% 25.21% 17.73% 9.75% 32.19%
Operating Expenses to Revenue		 103.37% 116.73% 122.98% 144.52% 107.67% 227.75%
Earnings before Interest and Taxes (EBIT)		 -46 -210 -254 -654 -56 -364
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -47 -211 -255 -705 46 -350
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 4.63 1.62 1.24 2.92 0.00 0.00
Price to Tangible Book Value (P/TBV)		 4.67 1.64 1.32 2.95 0.00 0.00
Price to Revenue (P/Rev)		 1.15 0.37 0.40 1.07 2.38 2.53
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.06 1.21 0.80 2.13 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1.01 0.28 0.42 0.92 3.04 2.53
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 48.58 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 39.72 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 2.39 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.62 0.18 -0.77 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.04 -0.64 0.00
Financial Leverage		 0.00 0.35 0.35 0.59 -0.77 0.00
Leverage Ratio		 1.83 2.14 1.96 3.26 -1.62 -5.69
Compound Leverage Factor		 1.83 2.14 1.96 3.26 -1.62 -5.69
Debt to Total Capital		 0.00% 0.00% 38.35% 14.92% -332.76% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 38.35% 11.78% -54.42% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 3.15% -278.35% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.62% -1,181.40% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 61.65% 84.46% 1,614.17% 100.00%
Debt to EBITDA		 0.00 0.00 -0.87 -0.13 2.78 0.00
Net Debt to EBITDA		 0.00 0.00 -0.07 0.31 0.76 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.03 2.33 0.00
Debt to NOPAT		 0.00 0.00 -1.25 -0.21 -3.24 0.00
Net Debt to NOPAT		 0.00 0.00 -0.10 0.47 -0.89 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.04 -2.71 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.44% 121.85% -272.96% 0.00%
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 -87 145 -123 -1,130 -1.03 0.00
Operating Cash Flow to CapEx		 2,239.40% -24,770.89% -4,565.17% -39,049.24% -17,099.28% -695,108.70%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -353.86 -0.03 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -88.42 -3.29 -6.90
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -88.65 -3.31 -6.91
Efficiency Ratios		 - - - - - -
Asset Turnover		 2.38 1.82 1.26 2.41 5.47 2,837.01
Fixed Asset Turnover		 263.87 231.81 275.07 672.99 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 341 286 579 634 -38 -0.02
Invested Capital Turnover		 4.37 2.90 1.82 4.93 -38.21 -16,146.73
Increase / (Decrease) in Invested Capital		 55 -293 -55 672 -38 0.00
Enterprise Value (EV)		 1,384 348 462 1,352 2,222 720
Market Capitalization		 1,578 464 444 1,565 1,736 720
Book Value per Share		 $0.68 $0.59 $0.75 $1.27 ($5.96) $0.00
Tangible Book Value per Share		 $0.67 $0.58 $0.70 $1.26 ($6.00) $0.00
Total Capital		 341 286 579 634 -38 -0.02
Total Debt		 0.00 0.00 222 95 127 0.00
Total Long-Term Debt		 0.00 0.00 0.00 20 106 0.00
Net Debt		 -195 -116 18 -216 35 0.00
Capital Expenditures (CapEx)		 1.56 0.58 4.47 0.72 0.69 0.02
Net Nonoperating Expense (NNE)		 11 66 162 130 97 109
Net Nonoperating Obligations (NNO)		 0.00 0.00 222 95 127 0.00
Total Depreciation and Amortization (D&A)		 -1.14 -1.42 -1.19 -51 102 14
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.44) ($0.71) ($1.42) ($0.32) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 490.02M 482.18M 476.24M 412.92M 406.32M 0.00
Adjusted Diluted Earnings per Share		 $0.00 ($0.44) ($0.71) ($1.42) ($0.32) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 490.02M 482.18M 476.24M 412.92M 406.32M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.32) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 510.91M 495.29M 479.55M 473.27M 130.11M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -32 -129 -194 -458 -39 -253
Normalized NOPAT Margin		 -2.35% -10.27% -17.57% -31.16% -5.37% -88.71%
Pre Tax Income Margin		 -3.37% -16.73% -22.98% -44.52% -7.67% -127.75%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -204.79 -1.56 -15.71
NOPAT to Interest Expense		 0.00 0.00 0.00 -143.35 -1.09 -10.99
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -205.02 -1.58 -15.71
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -143.58 -1.11 -11.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -42.46% -2.92% -1.87% -0.04% -0.70% 0.00%

Quarterly Metrics And Ratios for Clover Health Investments

This table displays calculated financial ratios and metrics derived from Clover Health Investments' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 33.27% 9.52% 8.16% 11.28% 7.60% 120.77% -64.23% -62.12% -63.67% -443.14% 100.45%
EBITDA Growth		 94.60% 68.46% 73.86% 124.81% 71.55% -4,979.69% 54.60% 74.48% -10.70% 99.47% 49.45%
EBIT Growth		 94.39% 68.39% 73.87% 124.88% 70.93% -5,890.02% 55.47% 72.32% -5.57% 100.63% 49.57%
NOPAT Growth		 94.39% 68.39% 73.87% 135.55% 70.93% -4,153.01% 55.47% 72.32% -5.57% 100.89% 49.57%
Net Income Growth		 93.35% 68.65% 77.92% 125.71% 73.60% 16.33% 45.07% 72.39% 3.82% 55.01% -118.64%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
Operating Cash Flow Growth		 -162.82% 66.74% 366.15% -15.83% -67.18% -23.27% -118.48% 235.75% 238.55% -161.14% 325.27%
Free Cash Flow Firm Growth		 -105.64% -128.47% -5.15% -23.48% -35.28% 336.23% 151.79% 153.81% 168.08% 106.99% -420.25%
Invested Capital Growth		 14.91% 19.12% -54.90% -65.57% -73.34% -50.53% -37.55% -47.04% -53.73% -8.68% 181.09%
Revenue Q/Q Growth		 37.21% 1.81% -7.09% 2.83% 12.61% 0.53% -4.41% -0.58% 121.74% -273.14% 1.22%
EBITDA Q/Q Growth		 94.20% -139.24% -236.50% 127.93% 65.42% -98.29% -29.53% 67.97% -6,074.23% 98.23% 27.19%
EBIT Q/Q Growth		 94.06% -144.14% -222.23% 131.02% 65.86% -101.87% -16.39% 63.76% -6,900.17% 101.55% 27.65%
NOPAT Q/Q Growth		 94.06% -144.14% -185.56% 144.31% 65.86% -101.87% -16.39% 63.76% -4,860.12% 102.22% 27.65%
Net Income Q/Q Growth		 94.23% -141.31% -223.58% 138.64% 72.80% -69.94% -43.92% 60.31% 13.80% -11.57% 27.67%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 27.27%
Operating Cash Flow Q/Q Growth		 81.02% -271.71% 11.68% 72.57% 110.05% -1,274.19% -135.32% -32.72% 137.75% -305.96% 359.52%
Free Cash Flow Firm Q/Q Growth		 36.22% -117.00% -34.42% -20.63% 221.77% -43.37% -47.09% -32.86% 2,068.75% 106.72% 45.03%
Invested Capital Q/Q Growth		 -1.49% -0.30% 5.32% 11.08% 2.12% -62.25% -19.58% -14.00% 89.51% -52.35% -31.81%
Profitability Metrics		 - - - - - - - - - - -
EBITDA Margin		 -0.27% -6.37% -2.71% 1.84% -6.79% -22.11% -11.21% -8.27% -25.68% 0.00% -8.83%
EBIT Margin		 -0.28% -6.37% -2.65% 2.02% -6.69% -22.06% -10.98% -9.02% -24.75% 0.00% -8.82%
Profit (Net Income) Margin		 -0.28% -6.56% -2.77% 2.08% -5.53% -22.91% -13.55% -9.00% -22.55% 0.00% -8.82%
Tax Burden Percent		 100.00% 103.00% 104.21% 103.08% 82.74% 103.85% 123.36% 99.76% 91.10% -7,186.52% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -0.91% -19.46% -4.53% 4.19% -8.63% -44.81% 0.00% -0.08% -5.41% 0.00% -22.64%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -5.90% 4.26% -9.39% -65.51% 0.00% -0.95% -6.68% 0.00% -28.01%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% -3.88% 3.98% -11.81% -22.61% 0.00% -2.47% -21.81% 0.00% -29.36%
Return on Equity (ROE)		 0.00% 0.00% -8.41% 8.17% -20.43% -67.42% -63.63% -2.54% -27.22% 0.00% -52.00%
Cash Return on Invested Capital (CROIC)		 -19.39% -27.76% 63.90% 84.58% 100.34% 33.63% 36.23% 52.11% 63.04% -20.27% -132.65%
Operating Return on Assets (OROA)		 -0.65% -15.15% -4.16% 2.75% -8.06% -40.16% 0.00% -0.09% -6.48% 0.00% -21.22%
Return on Assets (ROA)		 -0.65% -15.61% -4.33% 2.83% -6.67% -41.71% 0.00% -0.09% -5.91% 0.00% -21.22%
Return on Common Equity (ROCE)		 0.00% 0.00% -8.41% 8.17% -20.43% -67.42% -63.63% -2.54% -27.22% 0.00% -51.75%
Return on Equity Simple (ROE_SIMPLE)		 -7.47% 0.00% -26.71% -38.08% -54.68% 0.00% -70.57% -79.00% -104.20% 0.00% -112.90%
Net Operating Profit after Tax (NOPAT)		 -0.89 -15 -6.15 7.19 -16 -48 -24 -20 -56 1.17 -53
NOPAT Margin		 -0.19% -4.46% -1.86% 2.02% -4.68% -15.44% -7.69% -6.32% -17.33% 0.00% -6.18%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 1.38% -0.07% 0.76% 20.69% 2.85% 0.87% 1.27% 53.94% 5.37%
SG&A Expenses to Revenue		 12.77% 18.62% 16.62% 15.58% 17.09% 21.18% 19.79% 19.50% 21.42% 0.00% 8.20%
Operating Expenses to Revenue		 100.28% 106.37% 102.65% 97.98% 106.69% 122.06% 110.98% 109.02% 124.75% 0.00% 108.82%
Earnings before Interest and Taxes (EBIT)		 -1.27 -21 -8.79 7.19 -23 -68 -34 -29 -80 1.17 -75
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.25 -21 -8.97 6.57 -24 -68 -34 -26 -83 -1.34 -76
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.46 4.63 4.10 1.88 1.34 1.62 1.63 1.31 1.25 1.24 2.07
Price to Tangible Book Value (P/TBV)		 5.51 4.67 4.14 1.90 1.36 1.64 1.73 1.39 1.34 1.32 2.09
Price to Revenue (P/Rev)		 1.23 1.15 1.05 0.46 0.31 0.37 0.00 26.33 0.75 0.40 0.27
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 5.00 4.06 3.26 1.09 0.63 1.21 0.81 0.69 0.83 0.80 1.02
Enterprise Value to Revenue (EV/Rev)		 1.13 1.01 0.83 0.27 0.14 0.28 0.00 39.80 1.68 0.42 0.41
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 39.72 0.00 0.00 0.00 0.00 0.00 26.72 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 3.17 0.66 0.26 2.39 1.71 0.92 0.83 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 1.36 1.85 2.40 0.62 2.10
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05
Financial Leverage		 0.00 0.00 0.66 0.94 1.26 0.35 1.76 2.60 3.27 0.35 1.05
Leverage Ratio		 2.00 1.83 2.58 2.95 3.45 2.14 3.67 4.38 5.08 1.96 3.12
Compound Leverage Factor		 2.00 1.83 2.58 2.95 3.45 2.14 3.67 4.38 5.08 1.96 3.12
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 57.58% 64.96% 70.55% 38.35% 67.74%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 57.58% 64.96% 70.55% 38.35% 66.09%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.64%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 42.42% 35.04% 29.45% 61.65% 32.26%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -3.02 -3.29 -2.95 -0.87 -1.63
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.61 -1.19 -1.92 -0.07 -0.85
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.04
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -4.43 -4.79 -4.28 -1.25 -2.66
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.89 -1.73 -2.78 -0.10 -1.38
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.06
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.49%
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -44 -70 410 626 788 245 433 818 1,218 56 -836
Operating Cash Flow to CapEx		 -8,807.03% -27,248.57% 12,527.82% 11,273.80% 5,828.09% 0.00% -7,728.81% 15,020.62% 31,486.85% -5,400.26% 39,249.03%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,068.19
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 251.62
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 250.98
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 2.37 2.38 1.57 1.36 1.20 1.82 0.00 0.01 0.26 1.26 2.41
Fixed Asset Turnover		 290.39 263.87 270.76 266.15 262.46 231.81 0.00 4.70 157.89 275.07 1,285.02
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 336 341 342 325 292 286 759 943 1,097 579 1,215
Invested Capital Turnover		 4.73 4.37 2.44 2.08 1.84 2.90 0.00 0.01 0.31 1.82 3.67
Increase / (Decrease) in Invested Capital		 44 55 -417 -619 -805 -293 -456 -838 -1,274 -55 783
Enterprise Value (EV)		 1,679 1,384 1,114 355 184 348 611 654 908 462 1,240
Market Capitalization		 1,834 1,578 1,403 611 393 464 524 433 405 444 812
Book Value per Share		 $0.66 $0.68 $0.69 $0.65 $0.59 $0.59 $0.66 $0.68 $0.67 $0.75 $0.82
Tangible Book Value per Share		 $0.65 $0.67 $0.68 $0.65 $0.58 $0.58 $0.62 $0.64 $0.63 $0.70 $0.81
Total Capital		 336 341 342 325 292 286 759 943 1,097 579 1,215
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 437 613 774 222 823
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20
Net Debt		 -155 -195 -289 -255 -209 -116 88 222 503 18 428
Capital Expenditures (CapEx)		 0.19 0.32 0.40 0.40 0.45 -0.26 0.24 0.35 0.25 3.88 0.26
Net Nonoperating Expense (NNE)		 0.38 7.08 3.01 -0.22 2.95 23 18 8.60 17 85 23
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 0.00 0.00 0.00 437 613 774 222 823
Total Depreciation and Amortization (D&A)		 0.03 -0.01 -0.18 -0.62 -0.35 -0.16 -0.69 2.40 -2.98 -2.51 -0.07
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.09) ($0.06) ($0.15) $0.00 ($0.16)
Adjusted Weighted Average Basic Shares Outstanding		 497.06M 490.02M 490.18M 487.48M 486.37M 482.18M 480.77M 479.16M 478.81M 476.24M 477.69M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.09) ($0.06) ($0.15) $0.00 ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding		 497.06M 490.02M 490.18M 495.18M 486.37M 482.18M 480.77M 479.16M 478.81M 476.24M 477.69M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 508.92M 510.91M 501.11M 497.47M 1.05B 495.29M 487.64M 484.86M 482.65M 479.55M 477.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.89 -15 -6.53 5.36 -16 -46 -23 -17 -55 0.82 -53
Normalized NOPAT Margin		 -0.19% -4.46% -1.97% 1.51% -4.61% -15.00% -7.39% -5.28% -16.93% 0.00% -6.18%
Pre Tax Income Margin		 -0.28% -6.37% -2.65% 2.02% -6.69% -22.06% -10.98% -9.02% -24.75% 0.00% -8.82%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -186.85
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -130.80
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -187.50
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -131.44
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -186.60% -42.46% -13.45% -7.60% -4.13% -2.92% -2.39% -1.42% -1.01% -1.87% -1.43%

Frequently Asked Questions About Clover Health Investments' Financials

When does Clover Health Investments's fiscal year end?

According to the most recent income statement we have on file, Clover Health Investments' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Clover Health Investments' net income changed over the last 5 years?

Clover Health Investments' net income appears to be on a downward trend, with a most recent value of -$43.01 million in 2024, falling from -$363.74 million in 2019. The previous period was -$213.36 million in 2023. View Clover Health Investments' forecast to see where analysts expect Clover Health Investments to go next.

How has Clover Health Investments revenue changed over the last 5 years?

Over the last 5 years, Clover Health Investments' total revenue changed from $284.68 million in 2019 to $1.37 billion in 2024, a change of 381.5%.

How much debt does Clover Health Investments have?

Clover Health Investments' total liabilities were at $239.60 million at the end of 2024, a 15.7% decrease from 2023, and a 202,989.6% increase since 2019.

How much cash does Clover Health Investments have?

In the past 5 years, Clover Health Investments' cash and equivalents has ranged from $0.00 in 2019 to $299.97 million in 2021, and is currently $194.54 million as of their latest financial filing in 2024.

How has Clover Health Investments' book value per share changed over the last 5 years?

Over the last 5 years, Clover Health Investments' book value per share changed from 0.00 in 2019 to 0.68 in 2024, a change of -340,500.0%.


Related Companies

This page (NASDAQ:CLOV) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored